Objective:To investigate the long-term effect of bone marrow-derived cells (BMC) therapy on left ventricular systolic function in patients after acute myocardial infarction (AMI) by performing meta-analysis of randomized controlled trials with follow-up ≥2 years. Methods:Specific terms were used to conduct a systematic literature search of MEDLINE,EMBASE,the Cochrane Library and the Cochrane Central Register of Controlled Trials,and the China Biological Medicine Disk database from their inception to July 2012. A standardized form was used to extract information,and RevMan version 5.0 was used to analyze outcome data quantitatively. Results:Six trials comprising 551 patients were included. Compared with controls,BMC therapy significantly improved left ventricular ejection fraction (LVEF) (5.09%,95% CI:2.67% to 7.52%,P < 0.000 1). Subgroup analysis revealed that significant improvement of LVEF induced by BMC therapy could be observed in patients with baseline LVEF≤42%,but disappeared in those with baseline LVEF> 42%. Conclusion:Intracoronary BMC infusion in patients with AMI may further increase LVEF and improve left ventricular systolic function on top of standard therapy,and beneficial effects could last for more than 2 years. The findings need to be validated in the future.